Background Antiviral therapy for patients with non-cirrhotic chronic hepatitis B and minimally
raised alanine aminotransferase (ALT) is controversial. We aimed to investigate the efficacy …

Background and aim Long-term treatment with tenofovir disoproxil fumarate (TDF) has
demonstrated suppression of viral replication outside of China. This study aims to assess …

Methods Chinese hepatitis B e antigen (HBeAg)-positive and-negative chronic hepatitis B
patients with viremia and elevated alanine aminotransferase were randomized 2: 1 to TAF or …

AIM: To compare the efficacy and safety of tenofovir disoproxil fumarate (TDF) in Asian and
non-Asian chronic hepatitis B (CHB) patients. METHODS: The efficacy and safety of the …

Abstract Background and Aims Tenofovir disoproxil fumarate (TDF) demonstrated potent
and sustainable antiviral efficacy and a good safety profile in patients with chronic hepatitis …

Tenofovir disoproxil fumarate (TDF) has demonstrated long‐term efficacy and a high barrier
to resistance in multiple chronic hepatitis B (CHB) populations outside of China. This study …

Abstract Background and Aims We used real‐world data to evaluate the efficacy and safety
of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in …

Background Treatment with tenofovir disoproxil fumarate has been associated with renal
toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis …

Abstract Background & Aims Tenofovir disoproxil fumarate (TDF) is a first‐line treatment for
chronic hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF …

Background & Aims Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to
treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir …